Current challenges in diagnosing and treating nontuberculous mycobacterial pulmonary disease

Infections in Medicine

Volumn 23, Issue 9, 2006, Pages 425-433

  Gadkowski, L Beth ^a   Stout, Jason E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Mycobacterium abscessus; Mycobacterium avium; Mycobacterium intracellulare; Mycobacterium kansasii; Nontuberculous mycobacteria

Indexed keywords

AMIKACIN; AZITHROMYCIN; CLARITHROMYCIN; ETHAMBUTOL; ISONIAZID; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ARTHRALGIA; ARTICLE; BACTERIUM CULTURE; BRONCHIECTASIS; COUGHING; DIAGNOSTIC VALUE; FATIGUE; GASTROINTESTINAL TOXICITY; HEARING LOSS; HEMOPTYSIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LEUKOPENIA; LUNG DISEASE; LUNG NODULE; MYCOBACTERIOSIS; MYCOBACTERIUM LEPRAE; TINNITUS; WEIGHT REDUCTION;

EID: 34047116453     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Covert TC, Rodgers MR, Reyes AL, Stelma GN Jr. Occurrence of nontuberculous mycobacteria in environmental samples. Appl Environ Microbiol. 1999;65:2492-2496.
2. Kirschner RA Jr, Parker BC, Falkinham JO III. Epidemiology of infection by nontuberculous mycobacteria. Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium scrofulaceum in acid, brown-water swamps of the southeastern United States and their association with environmental variables. Am Rev Respir Dis. 1992;145(2 pt 1):271-275.
3. von Reyn CF, Maslow JN, Barber TW, et al. Persistent colonisation of potable water as a source of Mycobacterium avium infection in AIDS. Lancet. 1994;343:1137-1141.
4. Lockwood WW, Friedman C, Bus N, et al. An outbreak of Mycobacterium terrae in clinical specimens associated with a hospital potable water supply. Am Rev Respir Dis. 1989;140:1614-1617.
5. Rosenzweig DY. Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases. Chest. 1979;75:115-119.
6. Kim TC, Arora NS, Aldrich TK, Rochester DF. Atypical mycobacterial infections: a clinical study of 92 patients. South Med J. 1981;74:1304-1308.
7. Ahn CH, Lowell JR, Onstad GD, et al. A demographic study of disease due to Mycobacterium kansasii or M intracellulare-avium in Texas. Chest. 1979;75:120-125.
8. Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med. 1989;321:863-868.
9. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest. 1992;101:1605-1609.
10. Olivier KN, Weber DJ, Wallace RJ Jr, et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med. 2003;167:828-834.
11. Aksamit TR. Hot tub lung: infection, inflammation, or both? Semin Respir Infect. 2003;18:33-39.
12. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med. 1997;156(2 pt 2):S1-S25.
13. Corbett EL, Blumberg L, Churchyard GJ, et al. Nontuberculous mycobacteria: defining disease in a prospective cohort of South African miners. Am J Respir Crit Care Med. 1999;160:15-21.
14. Huang JH, Kao PN, Adi V, Ruoss SJ. Mycobacterium avium- intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. Chest. 1999;115:1033-1040.
15. Swensen SJ, Hartman TE, Williams DE. Computed tomographic diagnosis of Mycobacterium avium-intracellulare complex in patients with bronchiectasis. Chest. 1994;105:49-52.
16. Lynch DA, Simone PM, Fox MA, et al. CT features of pulmonary Mycobacterium avium complex infection. J Comput Assist Tomogr. 1995;19:353-360.
17. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000;162(4 pt 1):1277-1284.
18. Wickremasinghe M, Ozerovitch LJ, Davies G, et al. Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax. 2005;60:1045-1051.
19. Eckburg PB, Buadu EO, Stark P, et al. Clinical and chest radiographic findings among persons with sputum culture positive for Mycobacterium gordonae: a review of 19 cases. Chest. 2000;117:96-102.
20. Dutt AK, Stead WW. Long-term results of medical treatment in Mycobacterium intracellulare infection. Am J Med. 1979;67:449-453.
21. Ahn CH, Ahn SS, Anderson RA, et al. A four-drug regimen for initial treatment of cavitary disease caused by Mycobacterium avium complex. Am Rev Respir Dis. 1986;134:438-441.
22. Etzkorn ET, Aldarondo S, McAllister CK, et al. Medical therapy of Mycobacterium avium-intracellulare pulmonary disease. Am Rev Respir Dis. 1986;134:442-445.
23. Tsukamura M, Ichiyama S. Comparison of antituberculosis drug regimens for lung disease caused by Mycobacterium avium complex. Chest. 1988;3:821-823.
24. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment. Int J Tuberc Lung Dis. 2002;6:628-634.
25. Tsukamura M. Evidence that antituberculosis drugs are really effective in the treatment of pulmonary infection caused by Mycobacterium avium complex. Am Rev Respir Dis. 1988;137:144-148.
26. Ahn CH, Lowell JR, Ahn SS, et al. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis. 1983;128:1048-1050.
27. British Thoracic Society. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society. Thorax. 1994;49:442-445.
28. Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax. 2001;6:167-172.
29. Dunne M, Fessel J, Kumar P, et al. A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin Infect Dis. 2000;31:1245-1252.
30. Benson CA, Williams PL, Currier JS, et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis. 2003;37:1234-1243.
31. Wallace RJ Jr, Brown BA, Griffith DE, et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med. 1994;149:1335-1341.
32. Wallace RJ Jr, Brown BA, Griffith DE, et al. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med. 1996;153(6 pt 1):1766-1772.
33. Tanaka E, Kimoto T, Tsuyuguchi K, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1999;160:866-872.
34. Dautzenberg B, Piperno D, Diot P, et al. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France. Chest. 1995;107:1035-1040.
35. Wallace RJ Jr, Brown BA, Griffith DE, et al. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M intracellulare infection. J Infect Dis. 1995;171:747-750.
36. Griffith DE, Brown BA, Girard WM, et al. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin Infect Dis. 2001;32:1547-1553.
37. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis. 1993;147:1271-1278.
38. Brown BA, Griffith DE, Girard W, et al. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Clin Infect Dis. 1997;24:958-964.
39. Margolis DA, Iseman MD, Whelan G. High rate of adverse events associated with rifabutin therapy for pulmonary MAC: experience of a large referral center. In: Program and abstracts of the 43rd Annual Meeting of the Infectious Diseases Society of America; 2005; San Francisco. Abstract 256.
40. Griffith DE, Brown BA, Cegielski P, et al. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis. 2000;30:288-292.
41. Griffith DE, Brown-Elliott BA, Wallace RJ Jr. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis. 2003;37:1178-1182.
42. Shiraishi Y, Nakajima Y, Takasuna K, et al. Surgery for Mycobacterium avium complex lung disease in the clarithromycin era. Eur J Cardiothorac Surg. 2002;21:314-318.
43. Nelson KG, Griffith DE, Brown BA, Wallace RJ Jr. Results of operation in Mycobacterium avium-intracellulare lung disease. Ann Thorac Surg. 1998;66:325-330.
44. Woods GL. Susceptibility testing for mycobacteria. Clin Infect Dis. 2000;31:1209-1215.
45. Gardner EM, Burman WJ, DeGroote MA, et al. Conventional and molecular epidemiology of macrolide resistance among new Mycobacterium avium complex isolates recovered from HIV-infected patients. Clin Infect Dis. 2005;41:1041-1044.
46. Woods GL, Williams-Bouyer N, Wallace RJ Jr, et al. Multisite reproducibility of results obtained by two broth dilution methods for susceptibility testing of Mycobacterium avium complex. J Clin Microbiol. 2003;41:627-631.
47. Chatte G, Panteix G, Perrin-Fayolle M, Pacheco Y. Aerosolized interferon gamma for Mycobacterium avium-complex lung disease. Am J Respir Crit Care Med. 1995;152:1094-1096.
48. Bermudez LE, Inderlied CB, Kolonoski P, et al. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. Antimicrob Agents Chemother. 2001;45:217-222.
49. Rodriguez Diaz JC, Lopez M, Ruiz M, Royo G. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int J Antimicrob Agents. 2003;21:585-588.
50. Wallace RJ Jr, Brown-Elliott BA, Crist CJ, et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother. 2002;46:3164-3167.